Iqvia Holdings: Pay

Iqvia Holdings paid its 2 named executives $37.8M in total in FY2025 (Dec). CEO Ari Bousbib was paid $28.1M of that.

PayNo stock prices for these years
CEO pay is from each proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Pay of each named executive

Ari BousbibChairman and Chief Executive Officer
FY2025 (Dec)
FY2024 (Dec)
FY2022 (Dec)
FY2021 (Dec)
4 years
Alistair R. GrenfellPresident, Commercial Solutions
FY2025 (Dec)
1 year
Ronald E. BruehlmanExecutive Vice President, Chief Financial Officer
FY2022 (Dec)
FY2021 (Dec)
2 years
Eric M. SherbetExecutive Vice President, General Counsel and Secretary
FY2022 (Dec)
FY2021 (Dec)
2 years
W. Richard Staub, IIIPresident, Research & Development Solutions
FY2022 (Dec)
FY2021 (Dec)
2 years

CEO pay against the pay peers

In FY2024 (Dec), the median CEO pay of the 15 peers with pay on file was $23.7M. The CEO of Iqvia Holdings was paid $26.7M, 13% above the median.

  1. 1Thermo Fisher Scientific
  2. 2Eli Lilly & Co
  3. 3Iqvia Holdings
  4. 4International Business Machines
  5. 5Accenture
  6. 6Pfizer
  7. 7Amgen
  8. 8Biogen
  9. 9Gilead Sciences
  10. 10Merck & Co.
  11. 11Bristol Myers Squibb
  12. 12AbbVie
  13. 13Gartner
  14. 14Zoetis
  15. 15Cognizant Technology Solutions
  16. 16Regeneron Pharmaceuticals
  17. 17Agilent TechnologiesNot disclosed
  18. 18Avantor, Inc.Not disclosed
  19. 19Danaher CorporationNot disclosed
  20. 20ICON plcNot disclosed
  21. 21Laboratory Corp of America HoldingsNot disclosed
  22. 22ModernaNot disclosed
  23. 23Vertex Pharmaceuticals Inc.Not disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.